Evidence map›Paper›PMID 29325227›Full record

ArticleEuropean journal of clinical investigation2018

Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device.

Cheyenne C S Tseng, Manon M H Huibers, Lonneke H Gaykema, Erica Siera-de Koning, Faiz Z Ramjankhan, Alan S Maisel, Nicolaas de Jonge

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of clinical investigation, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Observational
  2. Current and novel biomarkers in cardiogenic shock.European journal of heart failure · 2025
    Review
  3. Review
  4. Observational
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. A Peek at LVADs Pumping to Recovery.Clinical Medicine Insights. Cardiology · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Cheyenne C S TsengDepartment of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.ORCID http://orcid.org/0000-0003-1622-5506
Manon M H HuibersDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Lonneke H GaykemaDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Erica Siera-de KoningDepartment of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.
Faiz Z RamjankhanDepartment of Cardiothoracic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.
Alan S MaiselDivision of Cardiology, University of California San Diego, San Diego, CA, USA.
Nicolaas de JongeDepartment of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands.
University Medical Center Utrecht · NLUniversity of California San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe interleukin-33 (IL-33)/suppressor of tumorigenicity 2 (ST2) pathway is suggested to play an important role in fibrosis, remodelling and the progression of heart failure (HF). Increased soluble (sST2) levels are associated with adverse outcome in the average HF population. Less is known about sST2 levels in end-stage HF. Therefore, we studied sST2 levels in end-stage HF and the effect of unloading by left ventricular assist device (LVAD) support on sST2 levels. METHOD AND

resultsSerial plasma measurements of sST2 were performed pre-implantation and 1, 3 and 6 months after (LVAD) implantation in 38 patients. sST2 levels were elevated in end-stage HF just prior to LVAD implantation (74.2 ng/mL [IQR 54.7-116.9]; normal <35 ng/mL) and decreased substantially during LVAD support, to 29.5 ng/mL [IQR 24.7-46.6](P < .001). Patients with INTERMACS profile I had significantly higher sST2 levels compared to patients in profile II and profile III. A moderate correlation was found between sST2 and C-reactive protein (r = .580, P < .010).

conclusionLevels of sST2 are elevated in end-stage HF patients with variability that suggests multiple inputs to a pro-inflammatory and pro-fibrotic pathway. Cardiogenic shock and increased C-reactive protein levels are associated with higher sST2 levels. LVAD support results in a significant drop in sST2 levels with normalization within 3 months postimplantation. This suggests that LVAD support leads to lessening of fibrosis and inflammation, which might eventually be used to target medical policy: explantation of the LVAD versus permanent use or cardiac transplantation.

Indexed as

Heart-Assist DevicesAdolescentAdultAgedBiomarkersC-Reactive ProteinFemaleHeart FailureHumansInterleukin-1 Receptor-Like 1 ProteinMaleMiddle AgedYoung AdultBiomarkersC-Reactive ProteinIL1RL1 protein, humanInterleukin-1 Receptor-Like 1 Proteinbiomarkerheart failureleft ventricular assist devicemechanical circulatory supportsoluble ST2

Identifiers

PMID29325227
PMCPMC5838535
OpenAlexW2783942881

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.